The company has achieved stable co-expression of
gp96/nCoV-S protein, as measured by both immunofluorescence and ELISA,
in its clinically validated human cell line, enabling selection of the
COVID-19 vaccine. These steps are necessary precursors to completion of
company’s vaccine in preparation for its manufacture and use in clinical
trials.
Heat Bio is on track to complete design and
development of the COVID-19 vaccine in July, and expects its gp96/nCoV-2
expressing cell line to be available for clinical-grade manufacturing
with partner, Waisman Biomanufacturing, in early August.
https://seekingalpha.com/news/3580407-heat-bio-making-headway-in-covidminus-19-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.